Latest Manufacturing News

CONNEQT Health reported a $2.6 million operating cash outflow in the September quarter but secured $2 million through a convertible note, while expecting a $1.6 million R&D tax refund to shore up liquidity.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

Terragen Holdings expands its probiotic product range into beef and lamb feedlots, secures key international approvals, and progresses large-scale trials while maintaining a $3 million cash reserve.

Camplify Holdings has locked in a $3.21 million strategic investment from JB Group, which will take a 12.7% stake and partner to accelerate growth through dealership integration and marketing.

CurveBeam AI reports a 33% increase in Q1 FY26 purchase orders, secures A$6.5 million in new funding, and finalizes a strategic joint venture for China distribution and manufacturing rights.

IperionX has boosted titanium powder production capacity by 60% and secured US$75 million in Department of War funding to scale up to 1,400 tonnes per annum by 2027, aiming to become the largest and lowest-cost US titanium producer.

BluGlass Limited reports a robust project pipeline exceeding US$100 million, bolstered by initial orders from Collins Aerospace and Infleqtion Inc, alongside strategic board appointments and a $6 million R&D tax rebate.

Aurora Labs has advanced its micro gas turbine propulsion program with critical durability testing, a new Defence contract phase, and a strategic $5.5 million capital raise to scale manufacturing and commercialisation.

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.

Lynas Rare Earths delivered record quarterly sales revenue of A$200.2 million in Q1 FY26, bolstered by a successful $932 million equity raise and strategic partnerships aimed at securing critical rare earth supply chains outside China.

Fluence Corporation reported a robust 72.9% revenue increase year-to-date Q3 2025, fueled by the Ivory Coast Addendum project, while maintaining its full-year guidance despite some margin pressures.